Navigation Links
A new indicator of poor prognosis in node-negative colorectal cancer patients
Date:3/4/2010

Tumor budding at the invasive tumor front of colorectal cancer is recognized as an independent prognostic factor significantly related to both lymph node and distant metastasis. Several lines of evidence seem to suggest that tumor buds may, to some extent, represent malignant colorectal cancer stem cells because of their potential for migration and re-differentiation locally and at sites of metastasis. However, phenotypic characterization of cancer stem cells in general is still debated although at least 8 putative stem cell markers have been suggested including CD166, CD44s, EpCAM, ALDH1, CD133, CD24, CD90, and ABCG5. Little is known about the potential of these proteins to act as prognostic biomarkers in patients with colorectal cancer and most of these proteins have never before been explored within tumor buds themselves.

A research article published on February 14, 2010 in the World Journal of Gastroenterology addressed this question. Considering the apparent stem cell-like properties of tumor buds and association of budding with adverse clinical outcomes, the research team led by Dr. Alessandro Lugli performed immunohistochemical staining of 8 putative cancer stem cell markers, namely CD166, CD44s, EpCAM, ALDH1, CD133, CD24, CD90, and ABCG5. The expression within tumor buds was evaluated, their frequency of occurrence and their potential prognostic significance in patients with colorectal cancer were determined.

Their findings showed that expression of EpCAM and particularly of ABCG5 within the tumor buds of colorectal cancer are frequent events. Moreover, expression of EpCAM or ABCG5 within tumor buds themselves has the potential to stratify patients with colorectal cancer into prognostic subgroups. This was particularly pronounced for patients with node-negative disease.

The results of this study could have important implications for patients with lymph node-negative colorectal cancer. Stratification of this group of patients could help to identify those likely to have a particularly poor outcome who could perhaps be considered for adjuvant therapy.

The study is characterized technically by an excellent application of immunohistochemistry and provides interesting evidence to aid the understanding of the correlation between cancer stem cell markers at the invasive front of colorectal cancer and prognosis. The findings suggest that EpCAM and ABCG5 in tumor buds may be useful biomarkers of poor outcome in this subgroup of patients. However, further studies are necessary to address the important issue of whether EpCAM- or ABCG5-positive tumor buds indeed represent migrating colorectal cancer stem cells.


'/>"/>

Contact: Jin-Lei Wang
wjg@wjgnet.com
86-105-908-0039
World Journal of Gastroenterology
Source:Eurekalert

Related medicine news :

1. Research highlights important indicators of early-stage ovarian cancer
2. Hospital quality indicator may not be linked to patient survival after colon cancer surgery
3. The American Nurses Association Hosts Conference on the National Database of Nursing Quality Indicators
4. Low levels of PYY hormone a very early indicator of type 2 diabetes
5. Diabetes Ten City Challenge Collaborative Model Shows Improved Patient Health Across Key Clinical Indicators
6. Impaired sense of smell may be early indicator of Parkinsons disease
7. Data Dimensions Assists Clients With Compliance of Present on Admission (POA) Indicator Reporting Requirements as Part of the April 1, 2008 Timeline
8. A new indicator for esophageal varix in alcoholic disease
9. ED an Indicator of Mens Health
10. Stanford blood scanner detects even faint indicators of cancer
11. Stakeholders and public should use 20 specific health indicators
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2017)... ... August 18, 2017 , ... ... at creating a transparent, verifiable database to help the cannabis industry move towards ... Paragon hopes to deliver a faster technology with lower fees. Paragon will build ...
(Date:8/19/2017)... ... August 19, 2017 , ... Praeclarus Press has ... These illustrations show the diversity of the breastfeeding mothers, using bright colors ... of sizes. These illustrations are also available on tote bags, notepads, smartphone cases, ...
(Date:8/19/2017)... ... August 19, 2017 , ... “Congratulations! It's A Boy! ... children to both their parents and God. “Congratulations! It's A Boy! God’s Gift: A ... a couple from Long Island, New York. , Published by Christian Faith Publishing, Dale ...
(Date:8/18/2017)... York, New York (PRWEB) , ... ... ... International Courier, LLC, d/b/a Quick International, LLC (“Quick”), a highly specialized asset-light ... announced it has entered into a definitive agreement to purchase Unitrans International ...
(Date:8/18/2017)... ... August 18, 2017 , ... ... devices. Through an educational webinar, they will present the line of epMotion automated ... learn how easy you can automate everyday pipetting tasks. , Ideal for scientists ...
Breaking Medicine News(10 mins):
(Date:8/7/2017)... , Aug. 7, 2017  Endo International plc (NASDAQ: ... agreements to resolve virtually all known U.S. mesh product ... to resolve the known remaining U.S. claims at reasonable ... beginning in the fourth quarter of 2017 and continuing ... its second quarter 2017 results, the Company intends to ...
(Date:8/2/2017)... Calif. , Aug. 2, 2017 ... Continental Who,s Who as a Pinnacle Lifetime Professional ... the Key Account Manager at Turing Pharmaceuticals, AG. ... negotiations, troubleshooting and relationship building.                ... has more than 25 years of experience as ...
(Date:8/1/2017)... 2017   CerSci Therapeutics , a non-opioid drug ... , has received notice from the National Institute on ... (NIH) that it has been awarded a Direct-to-Phase II ... in 2017 with an additional $1,000,000 to follow in ... application of their lead non-opioid drug candidate CT-044 to ...
Breaking Medicine Technology: